These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31120565)

  • 21. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States.
    Elledge RM; Clark GM; Chamness GC; Osborne CK
    J Natl Cancer Inst; 1994 May; 86(9):705-12. PubMed ID: 7908990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast.
    Innos K; Horn-Ross PL
    Breast Cancer Res Treat; 2008 Oct; 111(3):531-40. PubMed ID: 17978879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Racial differences in breast cancer, cardiovascular disease, and all-cause mortality among women with ductal carcinoma in situ of the breast.
    Berkman A; F Cole B; Ades PA; Dickey S; Higgins ST; Trentham-Dietz A; Sprague BL; Lakoski SG
    Breast Cancer Res Treat; 2014 Nov; 148(2):407-13. PubMed ID: 25326349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
    Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
    Zhou W; Jirström K; Amini RM; Fjällskog ML; Sollie T; Lindman H; Sørlie T; Blomqvist C; Wärnberg F
    BMC Cancer; 2013 Oct; 13():512. PubMed ID: 24171825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer incidence in black and white women stratified by estrogen and progesterone receptor statuses.
    Gleason MX; Mdzinarishvili T; Sherman S
    PLoS One; 2012; 7(11):e49359. PubMed ID: 23166647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. StatBite Lifetime Risk of Breast Cancer Subtypes by Race.
    J Natl Cancer Inst; 2011 Apr; 103(7):537. PubMed ID: 21436061
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences in breast cancer stage, treatment, and survival by race and ethnicity.
    Li CI; Malone KE; Daling JR
    Arch Intern Med; 2003 Jan; 163(1):49-56. PubMed ID: 12523916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Race, ethnicity and risk of second primary contralateral breast cancer in the United States.
    Watt GP; John EM; Bandera EV; Malone KE; Lynch CF; Palmer JR; Knight JA; Troester MA; Bernstein JL
    Int J Cancer; 2021 Jun; 148(11):2748-2758. PubMed ID: 33544892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Emerging Roles of Steroid Hormone Receptors in Ductal Carcinoma in Situ (DCIS) of the Breast.
    Villanueva H; Grimm S; Dhamne S; Rajapakshe K; Visbal A; Davis CM; Ehli EA; Hartig SM; Coarfa C; Edwards DP
    J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):237-248. PubMed ID: 30338425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
    Parise C; Caggiano V
    Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of Ductal Carcinoma
    Ryser MD; Hendrix LH; Worni M; Liu Y; Hyslop T; Hwang ES
    Cancer Epidemiol Biomarkers Prev; 2019 Aug; 28(8):1316-1323. PubMed ID: 31186262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Menstrual and reproductive characteristics and breast cancer risk by hormone receptor status and ethnicity: The Breast Cancer Etiology in Minorities study.
    John EM; Phipps AI; Hines LM; Koo J; Ingles SA; Baumgartner KB; Slattery ML; Wu AH
    Int J Cancer; 2020 Oct; 147(7):1808-1822. PubMed ID: 32064598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources.
    Akinyemiju T; Moore JX; Ojesina AI; Waterbor JW; Altekruse SF
    Breast Cancer Res Treat; 2016 Jun; 157(3):575-86. PubMed ID: 27255533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Purrington KS; Gorski D; Simon MS; Hastert TA; Kim S; Rosati R; Schwartz AG; Ratnam M
    Breast Cancer Res Treat; 2020 May; 181(1):145-154. PubMed ID: 32236827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Race and the prognostic influence of p53 in women with breast cancer.
    Dookeran KA; Dignam JJ; Holloway N; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
    Ann Surg Oncol; 2012 Jul; 19(7):2334-44. PubMed ID: 22434242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-negative breast cancers are increased in black women regardless of age or body mass index.
    Stead LA; Lash TL; Sobieraj JE; Chi DD; Westrup JL; Charlot M; Blanchard RA; Lee JC; King TC; Rosenberg CL
    Breast Cancer Res; 2009; 11(2):R18. PubMed ID: 19320967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
    Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.